

Jean-Frédéric Blanc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/561394/publications.pdf>

Version: 2024-02-01

16
papers

16,659
citations

623188

14
h-index

940134

16
g-index

18
all docs

18
docs citations

18
times ranked

16977
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	1.8	54
2	Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern!. <i>Annals of Surgery</i> , 2021, 274, 843-850.	2.1	15
3	Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches. <i>Hepatology</i> , 2021, 74, 1595-1610.	3.6	7
4	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	1.8	44
5	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 2678-2695.	1.3	37
6	ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice. <i>Hepatology Communications</i> , 2020, 4, 809-824.	2.0	33
7	Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. <i>Journal of Geriatric Oncology</i> , 2019, 10, 427-435.	0.5	23
8	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
9	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	1.8	525
10	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
11	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. <i>Nature Communications</i> , 2017, 8, 1315.	5.8	228
12	Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk. <i>Hepatology</i> , 2017, 66, 2016-2028.	3.6	75
13	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 859-870.	5.1	699
14	Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. <i>Hepatology</i> , 2009, 50, 481-489.	3.6	394
15	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
16	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. <i>Hepatology</i> , 2007, 46, 740-748.	3.6	554